Effects of different dosages of fluvastatin from different dosage forms on glycometabolism in rats with metabolic syndromes / 中国药学杂志

ABSTRACT

OBJECTIVE: To evaluate the effects of fluvastatin on insulin resistance and hs-CRP level in metabolic syndrome rat model. METHODS: Sixty male KM rats were randomly divided into two groups 10 rats in control (normal diet) and 50 rats in model (high lipid diet) group. By the end of the 4th week, 10 rats selected randomly from the model group were killed to verify the establishment of metabolic syndrome model. Since the 5th week, the remainder 40 rats were randomly divided into A, B, C and D groups, then were administered intragastrically with fluvastatin capsules at 6 mg · kg-1 · d-1, fluvastatin capsules at 12 mg · kg-1 · d-1, fluvastatin slow-release tablets at 12 mg · kg-1 · d-1 and saline, respectively, and all the rats were fed on normal diet for 4 weeks. All the rats were killed by the end of the 8th week. The levels of TC, TG, LDL-C, HDL-C, FBG, FINS, and hs-CRP were measured respectively and then homeostasis model assessment of insulin resistance was calculated. RESULTS: By the end of the 4th week, the metabolic syndromes model was established. At the end of the experiment, compared with group D, the levels of TC, TG and LDL-C were decreased significantly(P 0.05); compared with group B, the levels of TC, TG, LDL-C, hs-CRP, FBG, FINS and HOMA-IR were decreased significantly in group C (P < 0.05). CONCLUSION: Fluvastatin can reduce TC, TG, LDL-C, FINS, and hs-CRP levels and improve insulin resistance, the effects is more apparent at a large-dosage and with slow-release tablets especially, and that may attribute to its anti-inflammation effects.